| Bioactivity | FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of FLT3 and CHK1, with IC50s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML)[1]. |
| Invitro | FLT3/CHK1-IN-2 对 MV4-11 细胞具有抗增殖活性 (IC50: 0 --> FLT3/CHK1-IN-2 相关抗体: |
| In Vivo | FLT3/CHK1-IN-2 (20 mg/kg，口服) 具有良好的 PK 特性，Cmax 为 2213.07 ng/mL，AUC(0−t) 为 2736.58 h·ng /mL[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C18H23F3N6O2S |
| Molar Mass | 444.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Deng M, et al. Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1. RSC Med Chem. 2023 Dec 7;15(2):539-552. |